Cargando…

Osteopontin is a prognostic biomarker in non-small cell lung cancer

BACKGROUND: In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Rud, Ane Kongsgaard, Boye, Kjetil, Øijordsbakken, Miriam, Lund-Iversen, Marius, Halvorsen, Ann Rita, Solberg, Steinar K, Berge, Gisle, Helland, Åslaug, Brustugun, Odd Terje, Mælandsmo, Gunhild M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830440/
https://www.ncbi.nlm.nih.gov/pubmed/24215488
http://dx.doi.org/10.1186/1471-2407-13-540
_version_ 1782291490244919296
author Rud, Ane Kongsgaard
Boye, Kjetil
Øijordsbakken, Miriam
Lund-Iversen, Marius
Halvorsen, Ann Rita
Solberg, Steinar K
Berge, Gisle
Helland, Åslaug
Brustugun, Odd Terje
Mælandsmo, Gunhild M
author_facet Rud, Ane Kongsgaard
Boye, Kjetil
Øijordsbakken, Miriam
Lund-Iversen, Marius
Halvorsen, Ann Rita
Solberg, Steinar K
Berge, Gisle
Helland, Åslaug
Brustugun, Odd Terje
Mælandsmo, Gunhild M
author_sort Rud, Ane Kongsgaard
collection PubMed
description BACKGROUND: In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating serum levels of OPN were measured and single nucleotide polymorphisms (SNP) in the -443 position of the OPN promoter were analyzed. METHODS: Associations between immunohistochemical expression of S100A4, OPN and ephrin-A1 and relapse free and overall survival were examined using univariate and multivariate analyses. Serum OPN was measured by ELISA, polymorphisms in the -443 position of the tumor OPN promoter were analyzed by PCR, and associations between OPN levels and promoter polymorphisms and clinicopathological parameters and patient outcome were investigated. RESULTS: High expression of OPN in NSCLC tumors was associated with poor patient outcome, and OPN was a strong, independent prognostic factor for both relapse free and overall survival. Serum OPN levels increased according to tumor pT classification and tumor size, and patients with OPN-expressing tumors had higher serum levels than patients with OPN-negative tumors. S100A4 was a negative prognostic factor in several subgroups of adenocarcinoma patients, but not in the overall patient cohort. There was no association between ephrin-A1 expression and patient outcome. CONCLUSIONS: OPN is a promising prognostic biomarker in NSCLC, and should be further explored in the selection of patients for adjuvant treatment following surgical resection.
format Online
Article
Text
id pubmed-3830440
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38304402013-11-17 Osteopontin is a prognostic biomarker in non-small cell lung cancer Rud, Ane Kongsgaard Boye, Kjetil Øijordsbakken, Miriam Lund-Iversen, Marius Halvorsen, Ann Rita Solberg, Steinar K Berge, Gisle Helland, Åslaug Brustugun, Odd Terje Mælandsmo, Gunhild M BMC Cancer Research Article BACKGROUND: In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating serum levels of OPN were measured and single nucleotide polymorphisms (SNP) in the -443 position of the OPN promoter were analyzed. METHODS: Associations between immunohistochemical expression of S100A4, OPN and ephrin-A1 and relapse free and overall survival were examined using univariate and multivariate analyses. Serum OPN was measured by ELISA, polymorphisms in the -443 position of the tumor OPN promoter were analyzed by PCR, and associations between OPN levels and promoter polymorphisms and clinicopathological parameters and patient outcome were investigated. RESULTS: High expression of OPN in NSCLC tumors was associated with poor patient outcome, and OPN was a strong, independent prognostic factor for both relapse free and overall survival. Serum OPN levels increased according to tumor pT classification and tumor size, and patients with OPN-expressing tumors had higher serum levels than patients with OPN-negative tumors. S100A4 was a negative prognostic factor in several subgroups of adenocarcinoma patients, but not in the overall patient cohort. There was no association between ephrin-A1 expression and patient outcome. CONCLUSIONS: OPN is a promising prognostic biomarker in NSCLC, and should be further explored in the selection of patients for adjuvant treatment following surgical resection. BioMed Central 2013-11-11 /pmc/articles/PMC3830440/ /pubmed/24215488 http://dx.doi.org/10.1186/1471-2407-13-540 Text en Copyright © 2013 Rud et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rud, Ane Kongsgaard
Boye, Kjetil
Øijordsbakken, Miriam
Lund-Iversen, Marius
Halvorsen, Ann Rita
Solberg, Steinar K
Berge, Gisle
Helland, Åslaug
Brustugun, Odd Terje
Mælandsmo, Gunhild M
Osteopontin is a prognostic biomarker in non-small cell lung cancer
title Osteopontin is a prognostic biomarker in non-small cell lung cancer
title_full Osteopontin is a prognostic biomarker in non-small cell lung cancer
title_fullStr Osteopontin is a prognostic biomarker in non-small cell lung cancer
title_full_unstemmed Osteopontin is a prognostic biomarker in non-small cell lung cancer
title_short Osteopontin is a prognostic biomarker in non-small cell lung cancer
title_sort osteopontin is a prognostic biomarker in non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830440/
https://www.ncbi.nlm.nih.gov/pubmed/24215488
http://dx.doi.org/10.1186/1471-2407-13-540
work_keys_str_mv AT rudanekongsgaard osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT boyekjetil osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT øijordsbakkenmiriam osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT lundiversenmarius osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT halvorsenannrita osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT solbergsteinark osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT bergegisle osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT hellandaslaug osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT brustugunoddterje osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer
AT mælandsmogunhildm osteopontinisaprognosticbiomarkerinnonsmallcelllungcancer